Navigation Links
Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

NEW HAVEN, Conn., Nov. 3 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that Susan Froshauer, PhD, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00pm EST. The conference will be held from November 10-12, 2008 at the Palace Hotel, New York, NY.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococus pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone-resistant Gram-positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
2. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
5. DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc.
6. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
7. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
8. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
9. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
10. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
11. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Va. (PRWEB) , ... July 28, 2017 , ... ... of the Military Officers Association of America (MOAA), has announced the grant recipients ... portion of the $25,000 in grants:, , Falcon’s Landing ...
(Date:7/28/2017)... ... July 28, 2017 , ... Nominated for ... Chain Partners for 2017. MEBC received numerous client nominations from customers who ... Berger, SupplyChainBrain’s publisher, says “For 15 years running, SupplyChainBrain has published our much-anticipated ...
(Date:7/28/2017)... (PRWEB) , ... July 28, 2017 , ... ... today released its 2014-2017 summary report on the Global Advisory Panel on the ... healthcare challenges and priority professional issues gathered during the past three years at ...
(Date:7/28/2017)... ... July 28, 2017 , ... Date aired: July 17th, 2017 , Guest: ... of first generation immigrants before her, Rose Hong came to America to realize a ... the part of loving parents who made sure their daughter got to the U.S. ...
(Date:7/28/2017)... ... 28, 2017 , ... For over 20 years Sealy Baby has been creating ... We take tremendous pride in using some of nature’s best materials while integrating today’s ... innovative crib mattresses and crib bedding for infants and toddlers. ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Medical Products, a leader in medical product innovation and global patient ... for hospice patient care. ... Centurion Medical Products ... pain management and emotional comfort are part of a hospice,s primary ... preventing unneeded emergency department admission due to severe fecal impaction. One ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
Breaking Medicine Technology: